Method validation and application of protein biomarkers: Basic similarities and differences from biotherapeutics

Bioanalysis

Volumn 1, Issue 8, 2009, Pages 1461-1474

  Lee, Jean W ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG;

ANIMAL; CALIBRATION; CHEMICAL ANALYSIS; HUMAN; LIMIT OF DETECTION; QUALITY CONTROL; REVIEW; STANDARD;

ANIMALS; BIOLOGICAL MARKERS; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; LIMIT OF DETECTION; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; REFERENCE STANDARDS;

EID: 79953008926     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/BIO.09.130     Document Type: Review

References (52)

1. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074), 353-357 (2006).
2. Jadhav PR, Mehta MU, Gobburu JVS. How biomarkers can improve clinical drug development. Am. Pharm. Rev. 7, 62-64 (2004).
3. Kummar S, Kinders R, Rubinstein L et al. Compressing drug development timelines in oncology using Phase '0' trials. Nat. Rev. Cancer 7(2), 131-139 (2007).
4. Wong R, Cunningham D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J. Clin. Oncol. 26(35), 5668-5670 (2008).
5. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Therapeutics 81(1), 104-107 (2007).
6. US FDA. Guidance for Industry on Bioanalytical Method Validation: Availability. Center for Drug Evaluation and Research, Rockville, MD, USA (2001).
7. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
8. Smolec J, DeSilva B, Smith W et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22(9), 1425-1431 (2005).
9. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J. 9(2), E156-E163 (2007).
10. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
11. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9(1), E109-E114 (2007).
12. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006).
13. Lee JW, Weiner RS, Sailstad JM et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 22(4), 499-511 (2005).
14. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 14(19), 5967-5976 (2008).
15. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 153(4), 646-656 (2008).
16. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 9(1), E105-108 (2007).
17. Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 245(3), 219-223 (2008).
18. US FDA. Using disease, placebo, and drug prior knowledge to improve decisions in drug development and at FDA. Case Studies Across Companies Disease Models at FDA: Overview and Case Studies (Diabetes and Obesity). FDA, Rockville, MD, USA (2006).
19. Stoch SA, Wagner JA. Biomarker analysis as a decision-making tool in drug discovery and development: implications for peroxisome proliferator-activator receptors. Int. J. Pharm. Med. 21, 271-277 (2007).
20. Lee J, Pan Y, O'Brian P, Xu R. Development and validation of ligand-binding assays for biomarkers. In:Ligand-Binding Assays: Development, Validation and Implementation in the Drug Development. Khan MN, Findlay WA (Eds). John Wiley & Sons, NY, USA, 129-161 (2010).
21. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 9(2), E117-E122 (2007).
22. Banks RE. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin. Chem. 54(1), 6-7 (2008).
23. Ferguson RE, Hoschstrasser DF, Banks RE. Impact of preanalytical variable on the analysis of biological fluids in proteomic studies. Proteomics Clin. Appl. 1, 739-746 (2007).
24. Wu Y, Lee JW, Uy L et al. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J. Pharm. Biomed. Anal. 49(5), 1203-1212 (2009).
25. Clinical and Laboratory Standards Institute. Procedures for the Handling and Processing of Blood Specimens; Approved Guideline (Third Edition). Document number H18-A3 (2004).
26. Clinical and Laboratory Standards Institute. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture: Approved Standard (Sixth Edition). Document number H3-A6 (2007).
27. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia 50(10), 2042-2043 (2007).
28. Khatami M. Standardizing cancer biomarkers criteria: data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker. Cell Biochem. Biophys. 47, 187-198 (2007).
29. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. In:Genomics in Cancer Drug Discovery and Development. Hampton GM, Sikora K (Eds). Elsevier, London, UK, 269-298 (2007).
30. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B 877(13), 1259-1271 (2009).
31. Lee JW, Ma H. Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins. AAPS J. 9, E164-E170 (2007).
32. Sukovaty RL, Lee JW, Fox J et al. Quantification of recombinant human parathyroid hormone (rhPTH(1-84)) in human plasma by immunoassay: commercial kit evaluation and validation to support pharmacokinetic studies. J. Pharm. Biomed. Anal. 42, 261-271 (2006).
33. Hall M, Lee JW, Spahr C, Lu H, Ortiz R. Ligand binding-mass spectrometry methods for understanding macromolecular drug biotransformation and impact on immunoassay quantification. Presented at: 56th Annual ASMS Conference on Mass Spectrometry and Allied Topics. Denver, CO, USA, 1-5 June 2008.
34. Clinical and Laboratory Standards Institute. Evaluation of Matrix Effects; Approved Guideline (Second Edition). Document number EP14A2 (2005).
35. Lee J, Quarmby V, Yang J, Ahene A, Salimi-Moosavi H. Why do we care whether a LBA is measuring 'total' or 'free' protein therapeutic or biomarker? AAPS Ligand Binding Assay Bioanalytical Focus Group Newsletter. July (2008).
36. Oe T, Ackermann BL, Inoue K et al. Quantitative analysis of amyloid b peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/ negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(24), 3723-3735 (2006).
37. Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3(3), 644-652 (2004).
38. Li H, Rose MJ, Tran L et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J. Pharmacol. Toxicol. Meth. 59(3), 171-180 (2009).
39. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin. Chem. 53(4), 620-628 (2007).
40. Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J. Proteome Res. 5(11), 2928-2934 (2006).
41. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63(5), 548-561 (2007).
42. Rudge JS, Holash J, Hylton D et al. Inaugural article: VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl Acad. Sci. USA 104(47), 18363-18370 (2007).
43. Lowe PJ, Gautier A. On the ability to predict free ligand suppression when free ligand assays are not available or impossible. Presented at: Annual Meeting of the Population Approach Group in Europe. St Petersburg, Russia, 23-26 June 2009.
44. Tannenbaum S, Gautier A, Lowe PJ. A mechanism based binding model for the population pharmacokinetics and pharmacodynamics of canakinumab, a monoclonal antibody in development for rheumatoid arthritis. Presented at: American Association of Pharmaceutical Scientists Meeting. Atlanta, GA, USA, 17-19 November, 2008.
45. Moxness M, Tatarewicz S, Weeraratne D et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem. 51(10), 1983-1985 (2005).
46. Salimi-Moosavi H, Burns D et al. A novel approach for the measurement of 'total and free' target proteins in serum samples in the presence of antibody therapeutics. Presented at: AAPS National Biotechnology Conference. Toronto, ON, Canada, 22-25 June 2008.
47. Wayne PA. Protocols for determination of limits of detection and limits of quantitation; proposed guideline. Clinical and Laboratory Standards Institute. Document number EP17-A (2004).
48. Wang J, Lee J, Burns D et al. 'Fit-forpurpose' method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J. 11(2), 385-394 (2009).
49. Findlay JWA, Dillard RF. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 9, E260-267 (2007).
50. Bowsher RR, Sailstad JM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kB ligand. J. Pharm. Biomed. Anal. 48(5), 1282-1289 (2008).
51. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW. Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal. Chem. 78(10), 3271-3276 (2006).
52. Ray CA, Dumaual C, Willey M et al. Optimization of analytical and preanalytical variables associated with an ex vivo cytokine secretion assay. J. Pharm. Biomed. Anal. 41(1), 189-195 (2006).